Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
by
Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
© 2024 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy Do Not Sell or Share My Personal Information